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Abstract
Background: It is well established that bleeding activates the hematopoietic system to regenerate the loss of mature blood
elements. We have shown that hematopoietic stem cells (HSCs) isolated from animals challenged with an acute bleed
regulate osteoblast differentiation from marrow stromal cells. This suggests that HSCs participate in bone formation where
the molecular basis for this activity is the production of BMP2 and BMP6 by HSCs. Yet, what stimulates HSCs to produce
BMPs is unclear.
Methodology/Principal Findings: In this study, we demonstrate that erythropoietin (Epo) activates Jak-Stat signaling
pathways in HSCs which leads to the production of BMPs. Critically, Epo also directly activates mesenchymal cells to form
osteoblasts in vitro, which in vivo leads to bone formation. Importantly, Epo first activates osteoclastogenesis which is later
followed by osteoblastogenesis that is induced by either Epo directly or the expression of BMPs by HSCs to form bone.
Conclusions/Significance: These data for the first time demonstrate that Epo regulates the formation of bone by both
direct and indirect pathways, and further demonstrates the exquisite coupling between hematopoesis and osteopoiesis in
the marrow.
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Introduction
Osteoblasts play a central role in skeletal development. Derived
frompluripotent mesenchymalstemcells(MSCs),osteoblastsmature
along a specific lineage to become highly specialized synthetic cells.
As such, osteoblasts respond to many mechanical, local and systemic
stimuli that regulate mineralization while orchestrating bone
remodeling. Work by our group in the human system and others in
murine models have demonstrated that osteoblasts also constitute
part of the stromal cell support system in marrow for hematopoiesis
by participating in the formation of the HSC niche (reviewed in [1]).
In this capacity osteoblast-expressed cell-to-cell receptors (e.g., N-
Cadherin, Jagged, VCAM-1, Annexin II), soluble and cell-surface
associated cytokines, and growth factors all regulate HSC functions.
Each of these factors are in turn influenced by hormonal (e.g., PTH)
and local signals (e.g., BMPs, Ang-1) [1,2].
It is believed that cross talk between hematopoietic cells and
bone forming osteoblasts regulates each other’s function [3,4]. In
fact, as late as the 19th century bloodletting was a frequent
medical procedure for a number of conditions including the
treatment of metabolic bone diseases [5,6]. Since the mid 1990’s,
however, it has been known that direct marrow ablation, or
trauma is potent activators of osteogenic activities in vivo
[7,8,9,10,11,12]. It has also been demonstrated that blood loss, a
condition that stimulates hematopoietic stem cells (HSCs), may
also activate osteoprogenitor cells in the bone marrow to form
bone [12]. Animals that are subjected to an acute blood loss (1%
or 3% of body weight) had significant increases in mineral
appositional rates, osteoblast number, and serum levels of an
osteogenic growth peptide [12]. These findings suggest that
bleeding alone, without skeletal trauma, may induce an osteogenic
response that is systemic in nature. Yet, the mechanisms induced
by direct marrow injury and bleeding to stimulate bone formation
remains unclear [12].
We have also recently shown that HSCs isolated from animals
challenged with an acute bleed regulate osteoblast differentiation
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10853Epo Stimulates Bone Formation
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10853from mixed bone marrow stromal cells (BMSCs) and MSCs,
suggesting that HSCs actively participate in bone formation [2].
The molecular basis for this activity is the production of BMP2
and BMP6 by HSCs [2]. These findings support the reports that
show that an acute bleed activates bone formation in vivo
[7,8,9,10,11,12]. Yet, what stimulates HSCs to secrete BMPs is
unknown. We hypothesized that the factor that stimulates HSCs to
secrete BMPs and ultimately bone formation was erythropoietin
(Epo). Although Epo is best known for its role as a hematopoietic
hormone, recent findings that Epo receptors (EpoR) are expressed
in non-hematopoietic tissues (endothelial cells, neurons, tropho-
blast cells) has hastened the search for non-hematopoietic effects of
Epo [13,14,15,16,17]. Yet there are no examples in the literature
that directly link Epo to bone formation. In present study, we show
that Epo activates HSCs to produce BMPs. In addition, it was
found that Epo acts directly on BMSCs to induce osteoblastic
differentiation. Importantly, Epo stimulates bone formation in vivo
by targeting both HSCs and the osteoblastic niche. These findings
demonstrate that Epo directly and indirectly regulates the
formation of bone, and further demonstrates an exquisite coupling
between hematopoiesis and osteopoiesis in the marrow.
Results
Epo stimulates BMP expression by HSCs
We have demonstrated that HSCs respond to an acute bleed by
secreting BMPs, which are able to stimulate MSC differentiation
to osteoblastic lineage in vitro and in vivo [2]. What activates HSCs
to secrete BMPs is however unknown. We hypothesized that Epo
may serve as the link between bleeding and BMPs production by
HSCs. Therefore, to address the hypothesis, it was first determined
if the serum levels of Epo are able to increase during the same time
frame that HSC activation occurs. For these studies, animals were
bled and 3 days later serum was collected. As expected, serum Epo
levels rose in the bled animals (Figure 1A), whereas PTH, a
hormone known to stimulate bone formation [18], failed to
enhance the serum Epo levels (Figure 1A).
Epo is known to signal through the Epo receptor, a member of
the hematopoietic/cytokine/growth factor receptor family [19]. A
comparison of the expression of mRNA for the EpoR in HSCs
(isolated by means of the SLAM-family of receptors) demonstrated
that bleeding increased the mRNA levels for the EpoR (Figure 1B
left). Intriguingly, when HSCs were isolated from naı ¨ve animals
and treated with Epo in vitro, a similar increase in EpoR expression
was observed (Figure 1B right). Further evaluation of the
expression of the EpoR at the protein level was performed by flow
cytometry using Alexa488-conjugated anti-EpoR antibodies.
Approximately 10% of the HSCs isolated on the basis of
Lin
2Sca1
+cKit
+ (LSK) markers or 5% of HSCs isolated using
the SLAM-family of receptors express EpoR under basal
conditions (Figure 1C), suggesting that activation of resting
HSCs by Epo is possible.
To determine if Epo is able to signal through EpoR in HSCs,
cells were cultured for 12h in vitro in the presence or absence of
Epo [20]. In vitro, Epo stimulation increased the expression of
EpoR and resulted in the phosphorylation of Jak2 and Stat3 in
HSCs (isolated using LSK markers) (Figure 1D, quantified in
Figure S1A-C). Inclusion of the Jak2 and Stat3 phoshorylation
inhibitor AG490 (Calbiochem, La Jolla, CA) into the culture
prevented Epo activation of Jak2 and Stat3 (Figure 1D,
quantified in Figure S1A-C). Most importantly, when Epo is
used to stimulate HSCs in vitro, more BMP2 mRNA was observed
(Figure 1E, quantified in Figure1F). To confirm that the in vitro
observations are relevant in vivo, the BMP2 levels in HSCs (isolated
using the SLAM-family receptors) were examined in HSCs
recovered from the Epo-treated (6000 U/kg) or vehicle-treated
animals. When the animals were bled, Epo significantly stimulated
BMP levels in HSCs (Figure 1G), as seen before [2]. These data
suggest that HSCs express EpoR on their surfaces, and that Epo
induces BMP2 expression by HSC through the Jak2/Stat3
signaling pathways.
Epo acts directly on bone marrow stromal cells to induce
an osteoblastic phenotype
Recent findings suggest that non-hematopoietic cells express
EpoR, and therefore non-hematopoietic effects of Epo are possible
[21]. Next, it was determined if circulating Epo directly targets
stromal cells in the marrow to activate osteoblastic activities. To
determine if bone marrow stromal cells (BMSCs) express EpoR,
EpoR protein levels were first evaluated by flow cytometry
(Figure 2A). As shown Figure 2B, EpoR mRNA increases
following Epo Treatment. To evaluate if Epo stimulates
osteoblastic differentiation, BMSCs were cultured for 21 days in
mineralizing conditions (ascorbic acid & b-glycerol phosphate) in
the presence or absence of Epo and BMP2 (as a positive control).
As expected, BMP2 stimulated osteoblastic differentiation
(Figure 2C), including induction of the bone specific transcription
factor Runx2, osteocalcin (OCN) and bone sialoprotein (BSP).
Epo treatment of the culture similarly induced the expression of a
bone phenotype including induction of Runx2, OCN and BSP
(Figure 2C). In addition, Epo was able to increase mineral
deposition by the cultures (Figure 2D) and enhanced the
expression of Alkaline phosphatase (ALP) activity (Figure 2E).
These data suggest that BMSCs express EpoR, and that Epo
directly induces osteoblastic differentiation of BMSCs.
Epo induces osteoclastogenesis but not osteoclast
function
Since osteogenesis and osteoclastogenesis are functionally
linked, it was next determined if Epo directly regulates
Figure 1. HSCs express EpoR and Epo stimulates HSCs to express BMPs. (A) Serum Epo levels in sham (non-bled), bled animals, vehicle-
treated animals, or PTH treated animals (n=5 per group) were determined by ELISA. Data are presented as the mean 6 standard error of the mean.
Significant difference from the sham bled animals. (B) Real-time RT-PCR detection of EpoR mRNA levels in HSCs isolated using SLAM-family receptors.
In vivo: mRNA recovered from HSCs isolated directly from sham bled or animals bled 2 days prior. In vitro: mRNA recovered from naı ¨ve HSCs treated
with vehicle or rhEpo (10 U/ml) for 12 hours. The data were normalized to the expression of b-Actin. Data from a representative of three experiments
are presented as the mean 6 standard error of the mean. Significant differences from the sham bled animals or vehicle treatment groups. (C) FACS
analysis for EpoR expression by HSCs isolated using LSK or SLAM-family markers. (D) Western blot analysis for the expression of EpoR, P-Jak2, P-Stat3
expression by HSCs (LSK markers) treated with Epo with or without AG490 (an inhibitor of Stat3 and Jak2) for 12 h. P: phosphorylated. (E) Western
blot analysis for BMP2 expression by HSCs (LSK markers) treated with Epo with or without AG490 after 12 h, (F) Quantitative digital image analyses of
BMP2 expression. Data from a representative of three experiments are presented as the mean 6 standard error of the mean. Significant differences
from vehicle treatment groups. (G) Real-time RT-PCR detection of BMP2 mRNA levels expressed by HSCs (SLAM markers) following sham bleeding/
vehicle treatment, bleeding, or in vivo Epo (6000 U/kg) stimulation, 2 days prior to sacrifice (n=5 per group). Data are presented as the mean 6
standard error of the mean. Significant differences from sham bleeding/vehicle treatment groups.
doi:10.1371/journal.pone.0010853.g001
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(MMCs) were treated with Epo for 5 days. Receptor activator of
NFkb (RANKL) was included in the assays as a positive control of
osteoclastogenesis. At the conclusion of the studies, TRAP staining
was performed and multinucleated TRAP-positive cells in the
cultures were counted. As expected, the RANKL enhanced
osteoclastogenesis in MMCs (Figure 3A, quantified in
Figure 3B). Compared to the vehicle treatments, Epo stimulated
osteoclast formation by MMCs (Figure 3A, quantified in
Figure 3B). Next, to determine if Epo activates osteoclastic
activity, in vitro bone resorption assays were performed. Intrigu-
ingly, Epo had no effects on bone resorption induced by
osteoclasts, while RANKL induced bone resorption (Figure 3C,
quantified in Figure 3D). These data suggest that Epo induces
osteoclast formation, but alone does not stimulate osteoclastic
function in the marrow.
Epo stimulates bone formation in vivo
To directly assess the ability of Epo to stimulate bone formation
in vivo, new born mice were treated with vehicle or increasing
concentrations of Epo (1500–6000 U/kg, 3 times/week) for 28
days (Figure 4A). As a positive control for bone formation PTH
was administered (50 mg/kg, daily) [22]. Compared to control
vehicle treatments, Epo significantly increased the hematocrit
(Figure 4B), hemoglobin and red blood cell counts in blood of all
treated animals (Data not shown). Whereas PTH did not have
any discernable effects on any of the blood parameters examined,
nor did PTH alter serum Epo levels (Data not shown).
Critically, micro-computed tomography (mCT) of the vertebral
spines demonstrated that like PTH treatments, Epo significantly
increased bone mineral density (BMD) and bone volume fraction
(BVF), compared to vehicle control (Figure 4C, and quantified in
Figure 4D&E). Histomorphometric analyses of the long bones
also demonstrated that Epo increased the number of osteoblasts on
the bone surfaces of the treated animals compared to controls
(Figure 4F, quantified in Figure 4G).
To determine if Epo is able to regulate bone formation in
mature animals, the animal studies were repeated by starting the
Epo treatments when the animals were 4–6 weeks of age. For these
studies, 6000 U/kg of Epo was chosen as treatment dose, since this
dose showed significant skeletal effects on new born mice. Like
those shown in Figure 4, both BMD and BVF levels were
enhanced by Epo treatment in mature animals (Figure 5A, and
quantified in Figure 5B&C). To determine if Epo stimulated
induces MSCs differentiation along the osteoblastic lineage in vivo,
osteoblast colony-forming unit (CFU-OB) and fibroblast colony-
forming unit (CFU-F) assays were performed on marrow
recovered from the treated animals. Interestingly, Epo treatments
were significantly better able to induce CFU-OB and CFU-F
differentiation compared to the vehicle treatment (Figure 5D).
In previous work it has been demonstrated that HSC numbers
correlate with increases in the osteoblast numbers in marrow [23].
To determine if increases in HSC numbers accompanies an
increase in osteoblastic parameters, the numbers of HSC were
evaluated by FACS. Significantly, more HSCs (isolated using the
SLAM-family receptors) were found in the marrow from Epo-
treated animals (Figure 5E). Previously, it has been observed that
expansion of HSC pools is regulated in part by changes in marrow
levels of stromal derived factor-1 (SDF-1 or CXCL12). Accord-
ingly, CXCL12 levels in the marrow were evaluated by ELISA.
Surprisingly, Epo treatment did not enhance the CXCL12 levels
in the marrow, while PTH did (Figure 5F). These data suggest
that Epo treatment stimulates the bone formation in both neonatal
and mature animals in vivo, and further suggest that at least two
independent pathways to support the bone development. One
pathway is regulated via PTH. The other is regulated by Epo.
Bone formation depends upon the balance between the
osteoblastogenesis and the osteoclastogenesis. We have shown
that Epo stimulates osteoclast and osteoblast formation, and
activates HSCs. To determine the temporal relationships between
these events, osteoblast and osteoclast numbers were evaluated
over time. The levels of BMP2 mRNA expresed by HSCs were
significantly elevated in Epo-treated animals by two weeks
compared to vehicle-treated animals. However, the levels of
BMP2 expression expressed by HSCs returned near to base line by
4 weeks. Immunohistochemistry was used to confirm the BMP2
mRNA data. By staining for HSCs in the marrow
(CD150
+CD41
2CD48
2Lin
2 cells), it was noted that the number
of HSCs that express BMP2 was increased in the marrow at 2
weeks of Epo treatment (Figure 6A, and quantified in Figure 6B).
But by four weeks, the number of HSCs expressing BMP2 had
decreased. Epo stimulated formation of osteoclasts by 2 weeks, but
by 4 weeks, their numbers had begun to return to baseline levels
(Figure 6C, and quantified in Figure 6D). As expected, while
there were no remarkable differences in osteoblast numbers
between vehicle and Epo treatment at 2 weeks. However, by 4
weeks of treatment, Epo significantly increased the number of
osteoblasts observed in vivo (Figure 6E, and quantified in
Figure 6F). These data suggest that Epo first activates
osteoclastogenesis which is later followed by osteoblastogenesis
either directly or by the expression of BMPs by HSCs to induce
bone formation.
Discussion
It is well established that bleeding activates the hematopoietic
system to regenerate the loss of mature blood elements. To
accommodate the space required for this activity in marrow, bone
is resorbed. Yet, it was not clear how the lost bone is repaired,
when a hematopoietic steady state is re-established.
We previously demonstrated that HSCs regulate the develop-
ment of their own niche by producing of BMPs [2]. In a search for
the activity that stimulates HSCs to produce BMPs, we
hypothesized that the factor was Epo. Our data demonstrates
that a functional EpoR is expressed by HSCs, and that Epo
signaling leads to BMP production by HSCs. We also found that
Epo is able to stimulate BMSCs to form bone tissue directly. While
the precise cellular target in the mixed bone marrow stromal
population remains unclear, preliminary PCR results suggest that
very small cells with embryonic features (CD45
2Sca-1
+Lin
2 cells)
Figure 2. Mixed bone marrow stromal cells (BMSCs) are induced towards an osteoblastic phenotype by Epo. (A) FACS analysis for EpoR
expression by BMSCs. (B) Real-time RT-PCR determination for the expression of EpoR mRNA by BMSCs following vehicle or Epo treatment. The data
were normalized to b-Actin. Data from a representative of three experiments are presented as the mean 6 standard error of the mean. Significant
difference from vehicle treatment. (C–E) BMSCs were cultured for 21 days in mineralizing conditions (ascorbic acid & b-glycerol phosphate) in the
presence or absence of Epo (5–10 U/ml) and BMP2 (200 ng/ml; as a positive control). (C) The expression of Runx2, OCN, BSP, Collagen I mRNA were
detected by real-time RT-PCR. (D) In vitro mineralization in response to Epo was demonstrated by Alizarin red staining. Original magnification at 406.
Bar=100 microns. (E) Alkaline phosphatase activity measured in BMSC lysates following Epo treatment. Data from a representative of three
experiments are presented as the mean 6 standard error of the mean. Significant differences from vehicle treatment groups.
doi:10.1371/journal.pone.0010853.g002
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PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10853Figure 3. Epo supports osteoclastogenesis but not bone resorbing activities. To evaluate if Epo regulates osteoclastogenesis, marrow
mononuclear cells (MMCs)( 1 610
5 cells/well) were treated with rhEpo (5–10 U/ml) and/or RANKL (50 ng/ml (as a postitive control) in 96-well plates.
At 5 days, staining for TRAP was performed. (A) Representative light-microscopic images or cells expressing TRAP in mixed MMC culture. Original
magnification at 406. Bar=100 microns. (B) The numbers of TRAP-positive cells from quantified in (A). Data from a representative of three
experiments are presented as the mean 6 standard error of the mean. Significant differences from vehicle treatment groups. To examine if Epo
stimulate the function of osteoclasts, MMCs (5610
5 cells/well) were seeded on the resorbable artificial bone film-coated disks and incubated with
rhEpo (10–20 U/ml), or rhRANKL (50 ng/ml). (C) Representative micrographs demonstrating bone resorption and resorption area quantified in (D).
Original magnification at 206. Bar=100 microns. Data from a representative of three experiments are presented as the mean 6 standard error of the
mean. Significant differences from vehicle treatment groups.
doi:10.1371/journal.pone.0010853.g003
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EpoR (manuscript in preparation). Thus, by either activating
HSCs or BMSCs, Epo couples hematopoiesis with bone formation
(see model, Figure 7A&B).
Recently several groups have demonstrated that events centered
at the endosteal surfaces are critical for hematopoietic regulation
particularly by cells which share an osteoblastic phenotype in
mouse models [23,24]. These studies extend our work using
human cells in which we have shown that soluble signals secreted
by HSC establish a paracrine loop with osteoblasts that supports
early stem cell survival and suggest that HSCs modulate the
formation of a hematopoietic microenvironment directly. The
studies reported here are also in line with preclinical evidence in
rodents suggests that bleeding, in addition to stimulating
hematopoiesis, stimulates bone formation [7,8,9,10,11,12]. For
example, acute blood loss increases the rate of reparative bone
regeneration in animals [25]. However, most of the investigation
in this area has focused on what happens to bone under states of
hematopoietic stress. The enhanced production of hematopoietic
marrow has long been known to be associated with the conversion
of fatty marrow to hematopoietic marrow at the expense of bone.
This occurs particularly in the appendicular skeleton, and is
associated with accelerated bone resorption observed in chroni-
cally bled animals. Similar findings may be responsible for
progression of osteoporosis in postmenopausal women where
chronic menstrual bleeding may persist for up to 35 years [26].
Where it has been estimated that 70 ml of blood is lost monthly for
a total of ,850 ml/year and nearly 30 L over a life time [26].
Likewise, osteoporosis is a common finding in b-thalassemia, and
bone mineral densities are improved in transfused individuals [27].
On the other hand, an acute change in altitude, and by inference
Epo, may increase MSC numbers in patients with cytolytic
syndromes [28]. Here, it was noted that fibroblastic colony-
formation was 2 to 4 times increased after altitude change of
3,200 m [28].
Yet, direct evidence that Epo stimulates osteopoiesis or bone
formation is scarce and reports are often at odds with each other.
For example, it was recently demonstrated that Epo treatment in a
murine closed femur fracture model significantly improved healing
during early facture repair (days 0–6), but had little long term
effects [16]. These data suggest that Epo may induce BMSC
differentiation towards an osteoblastic phenotype. Conversely, the
presence of a developing callus after fracture inhibits erythropoi-
esis which could explain a mechanism for the recovery of the
hematopoietic system following marrow expansion [29]. Recent
work by Yamaza et al suggests that part of the mechanism
involved in the organizing of bone/hematopoietic marrow organ is
that EpoR-positive stromal cells may represent a small subset of
the heterogeneous population of the bone marrow [30]. Recently,
a condition described as adynamic bone disease which is
characterized by a defect in bone matrix formation and
mineralization in uremic patients has been defined by double
labeled bone biopsy specimens. While the pathogenesis of
adynamic bone disease is unclear, one hypothesis that has been
put forth is that Epo administration is associated with increased
indexes of bone matrix formation [31]. On the other side, the
effects of Epo on bone metabolism in patients receiving chronic
hemodialysis were directly assessed [31]. The results show that
exogenous Epo administration correlated with the increases in
1,25-dihydroxy-vitamin D (r=0.38, p,0.05) serum levels, intact
osteocalcin (r=0.42, p,0.05) and bone alkaline phosphatase
(r=0.53, p,0.005), but not intact parathyroid hormone (r=0.09)
[31]. The findings raise the possibility that for hemodialysis
patients with anemia, Epo may be associated with increased
formation of bone matrix [31]. Further supporting this notion,
while Epo administration increased osteoclast numbers in marrow
along the endosteal surfaces to facilitate the expansion of marrow,
cortical thickness was enhanced [32].
How in vivo administration of Epo increases bone has yet to be
determined. Our data show that the endogenous production of
osteoblasts from mixed stromal populations and that BMPs
produced by HSCs are likely candidates. At the same time, it is
unclear whether HSCs and/or stromal cells or both are the
cellular targets in vivo. One scenario worth considering is that Epo
activation of HSCs results in the formation of osteoclasts which in
the absence of nuclear factor kappaB-ligand (RANKL) and other
overt inflammatory stimuli are unable to progress to fully activated
osteoclasts capable of resorbing bone. The combined effects of
either HSC-derived BMPs and Epo effects on stromal cells in the
absence of activated osteoclast activity are likely to lead to a net
gain in bone formation. The balance between osteoblast and
osteoclast formation is crucial for bone formation. In the current
study, we found that Epo stimulates osteoclastic activity and
increases BMP-expressing HSC number in the marrow at 2 weeks
of Epo treatment, while Epo enhances osteoblastic formation at 4
weeks (Figure 6). These data suggest that Epo not only regulates
hematopoiesis but also participates in both osteoblastogenesis and
osteoclastogenesis to form bone (Figure 7A). Moreover, these
data further suggest that these events are coupled so that
osteoclastic resorption occurs first and then bone formation
follows (Figure 7B). It is also interesting to note that systemic
Epo treatments increased the number of HSCs in the marrow of
treated mice, but not by increasing marrow levels SDF-1/
CXCL12, while PTH did. At the same time, systemic PTH did
not result in increases in circulating Epo serum levels. Together
these data suggest that bone formation by Epo and PTH may
proceed along divergent pathways. PTH may work on osteoblastic
precursors and perhaps mature blood elements, while the Epo
pathway targets HSCs and osteoblastic precursors.
In summary, these data for the first time demonstrate that Epo
regulates the formation of bone by both direct and indirect
pathways, and further demonstrates the exquisite coupling
between hematopoesis and osteopoiesis in the marrow. We have
found that Epo/EpoR signaling in HSCs and/or stromal
populations may lead to expansion of osteoclastic and osteoblast
cell numbers. However, due to a predominant effect on
osteopoiesis, a net gain in bone formation occurs. Although
further study is warranted, these results suggest that targeting the
Epo pathway may serve as a therapeutic modality to treat skeletal
or mesenchymal abnormalities in humans.
Figure 4. Epo induces bone formation in vivo in neonatal animals. (A) Experimental model. To determine if Epo is able to stimulate bone
formation in vivo, newborn mice were injected with vehicle or increasing concentrations of Epo (1500–6000 U/kg, 3 times/week) for 28 days i.p. As a
positive control for bone formation, PTH was administered using an anabolic regime (50 mg/kg s.c., daily). n=5 per group. (B) Epo increases
hematocrit levels over the course of the 28 day experiment. (C) Micro-computed tomography measurements of the vertebral spines were performed
on fixed vertebral bodies at the conclusion of the study. Bone parameters including (D) BMD and (E) BVF were calculated from the micro-computed
tomography measurements. (F) Representative H&E staining of the long bones of treated animals. (G) Osteoblasts numbers were quantified on the
long bone sections with H&E staining. Original magnification at 606. Bar=100 microns. Data are presented as the mean 6 standard error of the
mean. Significant differences from vehicle treatment groups.
doi:10.1371/journal.pone.0010853.g004
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10853Figure 5. Epo induces bone formation in vivo in mature animals. To determine if Epo is able to stimulate bone formation in mature animals,
4-6-week-old mice were injected with vehicle or increasing concentrations of Epo (6000 U/kg, 3 times/week) for 28 days i.p. As a positive control for
bone formation, PTH was administered using an anabolic regime (50 mg/kg s.c., daily). n=5 per group. (A) The vertebral spines were fixed and 3-
dimensional micro-computed tomography measurements of the vertebral spines were performed. Bone parameters including (B) BMD and (C) BVF
were calculated. (D) Mixed marrow mononuclear cells derived from the treated-animals were cultured in mineralizing conditions (ascorbic acid & b-
glycerol phosphate). At 21 days, the cultures were examined for CFU-OB (Alizarin Red stainig) or CFU-F (Crystal Violet staining) colonies. (E) The
numbers of SLAM HSCs were counted by FACS. (F) The levels of CXCL12 in the marrow were measured by ELISA. Data are presented as the mean 6
standard error of the mean. Significant differences from vehicle treatment groups.
doi:10.1371/journal.pone.0010853.g005
Epo Stimulates Bone Formation
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10853Epo Stimulates Bone Formation
PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10853Materials and Methods
Induction of Hematopoietic Stresses
4-to 6-week-old C57BL/6 mice (Charles River Laboratories,
Wilmington, MA) were bled by jugular venipuncture under a
protocol approved by the University of Michigan Committee for
the Use and Care of Animals at the University of Michigan
(Approval #8418), as previously describe [2]. The mice were
anesthetized and approximately 20–30% of the calculated blood
volume (,0.55 ml for a 20 g mouse) was removed. Control mice
were also anesthetized and subjected to puncture without
hemorrhage.
HSC Isolation
The bone marrow were flushed from the femur, tibia, and
humeri with Dulbecco’s Phosphate-Buffered Saline (D-PBS)
(Invitrogen, Carlsbad, CA) without calcium and magnesium,
supplemented with 2% heat-inactivated fetal bovine serum (FBS;
Invitrogen). A single-cell suspension was obtained by gentle
agitation through the syringe. Debris and remaining cellular
aggregates were removed by passing the cell suspension over a
40 mm-mesh nylon cell strainer (BD Biosciences, San Diego, CA).
Cells were incubated first with a biotinylated anti-Lineage (CD5,
CD45R [B220], CD11b, Gr-1 [Ly- 6G/C], and Ter-119)
antibody cocktail (Miltenyi Biotec, Auburn, CA) for 10 min at
4uC, then rinsed and stained with an antibody cocktail of APC-
anti-stem cell antigen 1 (Sca-1) (clone D7; eBioscience, San Diego,
CA), PE/Cy7-anti-c-Kit (clone 2B8; BioLegend, San Diego, CA),
PE-anti-CD150 (clone TC15-12F12.2; BioLegend), FITC-anti-
CD41 (clone MWReg30; BD Biosciences), FITC-anti-CD48
(clone BCM-1; BD Biosciences), and FITC- anti-Biotin antibodies
(Miltenyi Biotec) for another 20 min at 4uC. HSCs isolated on the
basis of the signaling lymphocyteactivation molecule (SLAM)
family of receptors (SLAM HSCs) were sorted on a FACS
Vantage dual laser flow cytometer (Becton Dickinson, San Jose,
CA) by gating on cells that are Sca-1
+c-Kit
+CD150
+CD41
2C-
D48
2Lin
2, as previously described [2]. In some cases, Lin
2Sca-
1
+c-Kit
+ (LSK) cells were obtained using an antibody cocktail of
APC-anti-Sca-1 antibody, PE/Cy7-anti-c-Kit antibody, and
FITC-anti-Biotin antibody/biotinylated anti-Lineage antibody
cocktail.
Bone Marrow Cell Preparations
Bone marrow was flushed from the femurs, tibia, and humeri
with Hank’s buffer salt solution (Invitrogen). The cells were plated
in a-MEM with 10% FBS and 1% penicillin and streptomycin.
After 3 days, non-adherent cells were removed and fresh media
were replaced.
In Vitro Epo Treatments
SLAM HSCs, LSK cells, or bone marrow cells were incubated
with rhEpo (5–10 U/ml) (EPOGEN; Amgen, Thousand oaks, CA)
for 12 h. In some case, cells were also treated with Janus kinase 2
(Jak2)/Signal transducer and activator of transcription 3 (Stat3)
inhibitor (AG490; Calbiochem, La Jolla, CA).
Enzyme-Linked Immunosorbent Assays (ELISA)
Epo levels (R&D Systems, Minneapolis, MN) of the animal
serum, Alkaline phosphatase (ALP) activity levels (Sigma-Aldrich,
St. Louis, MO) of the cell lysates, and CXCL12 levels (R&D
Systems) of the bone marrow supernatants were determined by
double-antibody sandwich method assembled with commercially
available components, according to the directions of the
manufacturer. Data were normalized to the total protein.
RNA Extraction and Real-Time RT-PCR
Total RNA was isolated using RNeasy Mini or Micro Kit
(QIAGEN, Valencia, CA). First-strand cDNA was synthesized in a
20 ml reaction volume using 0.4 mg of total RNA or using
MessageBooster cDNA synthesis kit when evaluating mRNA levels
from isolated SLAM HSCs (Epicenter Biotechnologies, Madison,
WI). RT products were analyzed by real-time RT-PCR in
TaqManH Gene Expression Assays of several target genes: mouse
EpoR, BMP2, Runx2, osteocalcin (OCN), bone sialoprotein
(BSP), Collagen I, and b-Actin (Applied Biosystems, Foster City,
CA). Reactions without template and/or enzyme were used as
negative controls. The 2
nd step PCR reaction were run for 40
cycles (95uC for 15 sec and 60uC 1 min) after an initial single cycle
of 50uC for 2 min and 95uC for 10 min. The PCR product was
detected as an increase in fluorescence using an ABI PRISM 7700
instrument (Applied Biosystems). RNA quantity (CR) was normal-
ized to the housekeeping gene b-Actin control by using the
formula CR=2
(40-Ct of sample)-(40-Ct of control). The threshold cycle
(Ct) is the cycle at which a significant increase in fluorescence
occurs.
Flow Cytometry
LSK cells, SLAM HSCs, and bone marrow stromal cells
(BMSCs) were stained with Alexa Fluor 488 anti-mouse
monoclonal EpoR antibody (goat IgG; R&D systems) or IgG
isotype-matched control after cell sorting. Anti-mouse EpoR
antibody was stained with Alexa Fluor 488 monoclonal antibody
labeling kit (Molecular Probes, Carlsbad, CA), according to the
directions of the manufacturer. The levels of EpoR were analyzed
by a FACS Vantage dual laser flow cytometer (Becton Dickinson).
Western Blot Analyses
SDS-PAGE was performed in 10% polyacrylamide gels. After
electrophoresis, the proteins were transferred to polyvinylidene
difluoride membrane (Bio-Rad Laboratories, Hercules, CA). The
membranes were then incubated with the primary antibody (The
anti-EpoR antibody, R&D systems; the antibodies to phosphor-
ylated Jak2 and Stat3, Cell Signaling Technology, Danvers, MA;
the anti-BMP2 antibody, R&D systems; and the anti-Tubulin
antibody, Sigma-Aldrich) overnight, and the secondary antibody
(anti-species specific horseradish peroxidase, Cell Signaling
Figure 6. Epo regulates the balance between the osteoblastogenesis and the osteoclastogenesis. To determine if Epo is able to
stimulate bone formation in mature animals, 4-6-week-old mice were injected with vehicle or increasing concentrations of Epo (6000 U/kg, 3 times/
week) for 28 days i.p. n=5 per group. At 2 weeks and 4 weeks, animals were sacrificed and the long bones were prepared for immunohistochmistry.
(A) Representative elements of the marrow triple-stained with anti-CD150 antibodies, anti-BMP2 antibodies, and anti-lineage antibody cocktail. (B)
CD150
+BMP2
+CD41
2CD48
2Lin
2 area were quantified on the long bone sections. Original magnification at 606. Scale Bar=50 microns. (C)
Representative TRAP staining of the long bones of treated animals. (D) Osteoclasts numbers were quantified on the long bone sections with Trap
staining. Original magnification at 606. Bar=100 microns. (E) Representative H&E staining of the long bones of treated animals. (F) Osteoblasts
numbers were quantified on the long bone sections with H&E staining. Original magnification at 606. Bar=100 microns. Data are presented as the
mean 6 standard error of the mean.
doi:10.1371/journal.pone.0010853.g006
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PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e10853Figure 7. Coupling of hematopoiesis with osteopoiesis by Epo. Erythropoietin (Epo) is best known as a hematopoietic hormone. Epo is now
known to have a number of non-hematpoietic roles. However, what is not clear is how the bone compartment recovers. (A) Model of hematopoetic/
osteopoiesis coupling by Epo. An acute bleed activates the kidney O2 sensors to secrete Epo. In the marrow, Epo activates hematopoietic stem cell
(HSC) or progenitor cell (HPC) to enter the cycle (Green line), which results in the expansion of hematopoietic organ at the expense of the bone
tissue by activating osteoclastogenesis. Ultimately, expansion of the hematopoietic organ leads to the restoration of the formed elements of the
blood (Red lines). At the same time, Epo acts directly on mesenchymal stem cells (MSCs) and mixed bone marrow stromal cells (BMSCs) to induce
bone formation. Ultimately, activation of MSCs and BMSCs results in the restoration of the bone tissues (Blue lines). In addition to the direct effects
of Epo on HSCs, HPCs, and BMSCs, Epo activates HSCs and HPCs to secrete BMPs that target MSCs/BMSCs to reprogram the cells to differentiate into
osteoblasts to regenerate the lost bone tissue. Moreover, the osteoblasts that are induced by Epo directly or indirectly support hematopoiesis as a
bone marrow niche (Orange lines). (B) Time plot graph of events activated by Epo. Elevation of circulating Epo levels (Purple line) facilitates
expansion of the HSCs/HPCs to restore formed blood elements lost during an acute bleed (Green line), and to activate osteoclastogensis to expand
the marrow cavity (Red line). At the same time Epo induces BMPs expression by HSCs/HPCs to promote bone formation indirectly (Orange line). At
a later time, osteoblast number increases in the marrow stimulated directly by Epo’s actions on MSCs/BMSCs and indirectly by BMPs secreted by
HSCs/HPCs (Blue line). Together, Epo plays a critical and important role in cross talk between hematopoiesis and osteopoiesis by both direct and
indirect pathways.
doi:10.1371/journal.pone.0010853.g007
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PLoS ONE | www.plosone.org 12 May 2010 | Volume 5 | Issue 5 | e10853Technology) was added. Finally the proteins were visualized by
autoradiography using an enhanced chemiluminescence detection
system (Amersham Pharmacia, Piscataway, NJ). The densities of
the bands were quantified with Image J software (version 1.40;
National Institutes of Health (NIH), Bethesda, MD).
Mineralization Assays
BMSCs (2610
5 cells/well) were plated onto a 24-well culture
plate with osteogenic media containing 50 mg/ml ascorbic acid
(Sigma-Aldrich) and 10 mM b-glycerophosphate (Sigma-Aldrich).
BMSCs were treated with either vehicle as negative control,
rhBMP2 (200 ng/ml) (R&D Systems) as positive control, or rhEpo
(5–10 U/ml). At 14 days, osteoblastogenesis from BMSCs were
evaluated by Alizarin Red staining (Sigma-Aldrich).
In Vitro Osteoclastogenesis
Marrow mononuclear cells (MMCs)( 1 610
5 cells/well) were
plated onto 96-well culture plates. Cells were treated with
rhRANKL (50 ng/ml) (R&D Systems) and/or rhEpo (5–10 U/
ml) every other day for 7 days. Thereafter, osteoclastogenesis were
evaluated by TRAP staining (Sigma-Aldrich).
In Vitro Bone Resorption Assays
Bone resorption assays were performed as previously described
[33]. MMCs (5610
5 cells/well) were seeded on the resorbable
artificial bone film-coated disks (Becton Dickinson) and incubated
with vehicle, rhEpo (10–20 U/ml), or rhRANKL (50 ng/ml).
After 3 weeks of culture, the mean area of resorption from five
randomly selected fields was analyzed.
In Vivo Bone Formation Model
Newborn or 4-to 6-week-old C57BL/6 mice (Charles River
Laboratories, Wilmington, MA) were treated with 50 ml of vehicle
(0.9% saline) as negative control, parathyroid hormone (50 mg/kg,
per day) (hPTH(1–34); Bachem, Torrence, CA) as positive control,
or rhEpo (1500–6000 U/kg, three times per week) by intraper-
itoneal injection in for 28 days.
Micro-computed Tomography Evaluations
Lumbar vertebrae were harvested at 28 days of treatment. For
micro-computed tomography (mCT) analysis, specimens will be
scanned at 8.93 mm voxel resolution on an EVS corp. mCT
scanner (London, Ontario, Canada), with a total of 667 slices per
scan. GEMS MicroViewH software was used to make a 3-D
reconstruction from the set of scans. A fixed threshold (1,000) was
used to extract the mineralized bone phase, and bone mineral
density (BMD), and bone volume fraction (BVF) were calculated.
Immunohistochemistry
Seven mm sections of the decalcified long bones were then cut
with a microtome (Leica RM2125 RT; Leica Microsystems,
Bannockburn, IL) and stained with hematoxylin and eosin (H&E)
and TRAP staining kit (Kamiya biomedical company, Seattle,
WA). Total bone areas were measured using a computer-assisted
bone histomorphometric analyzing system (Image-Pro Plus v.5.1;
Media Cybernetics, Silver Spring, MD).
Immunohisto-fluorescence Assays
Seven mm frozen sections were fixed in acetone at 220uCf o r
10 min and were blocked with Image-iT FX signal enhancer
(Invitrogen) for 30 min. The slides were incubated overnight at 4uC
with anti-CD150 monoclonal antibody (BD Biosciences) (pre-stained
with ZenonH Alexa FluorH 405 mouse IgG1 labeling kit; Invitrogen)
and anti-BMP2 purified Goat IgG antibody (R&D Systems) (pre-
stained with ZenonH Alexa FluorH 555 Goat IgG labeling kit;
Invitrogen). The next day, the slides were incubated for 4 h at 4uC
with FITC-anti-mouse CD3e, Ly-76, CD45, CD41, and CD48
antibodies (eBioscience). Confocal laser scanning was performed with
a FV500 confocal laser-scanning microscope (Olympus, Center
Valley, PA). CD150
+BMP2
+CD41
2CD48
2Lin
2 area was measured
with Image Pro 5.1 program.
Colony Formation Assays
BMSCs (1610
6 cells/well) that were isolated from vehicle-
treated, PTH-treated, or Epo-treated 4-to 6-week-old C57BL/6
mice were plated onto a 6-well culture plate with osteogenic media
containing 50 mg/ml ascorbic acid and 10 mM b-glycerophos-
phate for 21 days. For osteoblast colony-forming unit (CFU-OB)
and fibroblast colony-forming unit (CFU-F) enumeration, the
cultures were fixed with 10% normal buffered formalin, and
stained with Alizarin Red and Crystal Violet (Sigma-Aldrich),
respectively. Colonies with greater than 50 cells are counted.
Statistical Analyses
Numerical data are expressed as mean 6 standard error of the
mean. Statistical analysis was performed by ANOVA or unpaired
two-tailed Student’s t test using the GraphPad Instat statistical
program (GraphPad Software, San Diego, CA) with significance at
P,0.05. For the real-time RT-PCR assays, a Kruskal-Wallis test
and Dunn’s multiple comparisons tests were utilized with the level
of significance set at P,0.05.
Supporting Information
Figure S1 Quantitative analysis of Western blots. The densities
of the western blot bands were quantified with ImageJ software.
(A) Quantitative analysis of (A) EpoR, (B) P-Jak2, and (C) P-Stat3
in HSCs (SLAM markers) that were treated with Epo with or
without AG490 after 12 h in Figure 1D. Data are presented as the
mean 6 standard error of the mean from triplicate determina-
tions. P: phosphorylated.
Found at: doi:10.1371/journal.pone.0010853.s001 (0.21 MB TIF)
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